X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FULFORD INDIA NATCO PHARMA/
FULFORD INDIA
 
P/E (TTM) x 16.9 398.8 4.2% View Chart
P/BV x 18.3 6.2 293.9% View Chart
Dividend Yield % 0.6 0.1 740.0%  

Financials

 NATCO PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FULFORD INDIA
Mar-14
NATCO PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs877942 93.1%   
Low Rs424450 94.1%   
Sales per share (Unadj.) Rs223.4691.4 32.3%  
Earnings per share (Unadj.) Rs31.111.5 271.1%  
Cash flow per share (Unadj.) Rs40.315.4 262.2%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.3 267.6%  
Book value per share (Unadj.) Rs219.5380.0 57.8%  
Shares outstanding (eoy) m33.073.90 847.9%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.0 289.1%   
Avg P/E ratio x20.960.7 34.5%  
P/CF ratio (eoy) x16.145.3 35.6%  
Price / Book Value ratio x3.01.8 161.7%  
Dividend payout %16.117.4 92.2%   
Avg Mkt Cap Rs m21,5042,714 792.2%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m1,128505 223.3%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m7,3892,696 274.0%  
Other income Rs m167125 133.3%   
Total revenues Rs m7,5562,822 267.8%   
Gross profit Rs m1,793-46 -3,864.9%  
Depreciation Rs m30415 2,002.6%   
Interest Rs m36610 3,854.7%   
Profit before tax Rs m1,29054 2,375.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m30910 3,215.6%   
Profit after tax Rs m1,02745 2,298.4%  
Gross profit margin %24.3-1.7 -1,410.4%  
Effective tax rate %23.917.7 135.4%   
Net profit margin %13.91.7 838.8%  
BALANCE SHEET DATA
Current assets Rs m3,6811,738 211.8%   
Current liabilities Rs m3,123545 573.3%   
Net working cap to sales %7.644.3 17.1%  
Current ratio x1.23.2 36.9%  
Inventory Days Days8948 184.6%  
Debtors Days Days594 1,363.3%  
Net fixed assets Rs m7,68512 64,581.5%   
Share capital Rs m33139 847.9%   
"Free" reserves Rs m6,6701,443 462.2%   
Net worth Rs m7,2591,482 489.8%   
Long term debt Rs m9550-   
Total assets Rs m11,9572,077 575.8%  
Interest coverage x4.56.7 67.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 47.6%   
Return on assets %11.72.6 446.6%  
Return on equity %14.23.0 469.3%  
Return on capital %20.74.3 481.4%  
Exports to sales %39.40-   
Imports to sales %5.724.5 23.3%   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421659 63.9%   
Fx inflow Rs m3,44517 20,031.4%   
Fx outflow Rs m703673 104.4%   
Net fx Rs m2,743-656 -418.1%   
CASH FLOW
From Operations Rs m1,44090 1,600.3%  
From Investments Rs m-1,089105 -1,041.3%  
From Financial Activity Rs m-353-14 2,501.4%  
Net Cashflow Rs m-1181 -0.8%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 3.8 206.3%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.2 122.6%  
Shareholders   25,395 4,783 530.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS